Novo Nordisk Expands AI Partnership With Valo Health
Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs
Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, Novo will collaborate with Valo to discover and develop up to 20 new treatments for obesity, type 2 diabetes, and cardiovascular diseases.
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to 20 programs.
PharmiWeb · 1d
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI).
Contract Pharma · 2d
Novo Nordisk, Valo Health Expand Cardiometabolic Drug Discovery Pact
The companies entered the agreement in 2023 to jointly advance as many as 11 drug programs, mainly targeting cardiovascular diseases. Under the terms, Valo was initially entitled to receive as much as $2.7 billion in milestone payments as well as R&D funding and royalty payments from Novo Nordisk.
The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...
Valo Health’s Rho kinase (ROCK ... Novo Nordisk pays $60M for 3 preclinical assets as part of AI-powered cardio collab ...
Bagsværd, Denmark Friday, January 10, 2025, 11:00 Hrs [IST] ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results